Efficacy News and Research

RSS

UK announces research partnership with Atomwise to explore potential COVID-19 therapies

The University of Kentucky announced a research collaboration with Atomwise, an industry leader in using artificial intelligence (AI) for small molecule discovery, to explore potential COVID-19 therapies

23 Jun 2020

FDA approved drugs active against COVID-19

With the rapid spread of the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) throughout the world, causing the current COVID-19 pandemic, there is an urgent need for new antivirals and vaccines to combat its spread. The current study published on the preprint server bioRxiv in June 2020 shows some of the results of the extensive repurposing of already FDA-approved drugs.

23 Jun 2020

First clinical trial in South Africa for Covid-19 vaccine begins

The first clinical trial in South Africa and on the continent for a Covid-19 vaccine was announced today, 23 June 2020, at a virtual press conference hosted by the University of the Witwatersrand, Johannesburg (Wits).

23 Jun 2020

Study: Increased use of human antibiotics on rice crops may fuel antibiotic resistance

Farmers in parts of Asia are spraying antibiotics deemed "critical" for human medicine on rice crops, raising fears they may be fuelling antibiotic resistance, say researchers.

23 Jun 2020

Jubilant Therapeutics announces preclinical data of dual LSD1 and HDAC6 inhibitor at AACR 2020

Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced that preclinical data of dual LSD1 and HDAC6 inhibitor JBI-802, will be presented in a poster session at the American Association for Cancer Research 2020 Virtual Annual Meeting II.

23 Jun 2020

Characterizing SARS-CoV-2 convalescent plasma

A new study published on the preprint server bioRxiv in June 2020 uses serologic correlates to assess the efficacy of convalescent plasma. This will also help to classify donor plasma as more or less potent at neutralizing the virus.

23 Jun 2020

Growth, adaptation and neutralization of SARS-CoV-2 with acute-phase serum

One recent study published on the preprint server bioRxiv in June 2020 reports the results of growing and characterizing the virus, as well as the development of neutralizing antibodies in the serum of acutely infected hospitalized patients with COVID-19.

22 Jun 2020

Three vaccine candidates race to combat SARS-CoV-2

As the coronavirus disease (COVID-19) ravages across the globe, scientists are racing to develop an effective vaccine to combat the viral infection. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the disease has infected nearly 9 million people.

22 Jun 2020

Favipiravir has weak effect on SARS-CoV-2 and Hydroxychloroquine none at all in hamster model

A new study from Belgian researchers shows that antiviral drug Favipiravir could have a weak effect against the dreaded novel coronavirus or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as seen in hamster models. However, the study also finds there is no efficacy of the much-touted drug Hydroxychloroquine.

22 Jun 2020

Novel vaccine platform against COVID-19 based on engineered human mesenchymal stem cells

In a recent groundbreaking bioRxiv paper, Chinese researchers describe a novel approach towards coronavirus disease (COVID-19) vaccine design based on engineered human mesenchymal stem cells, with favorable and promising antibody response.

22 Jun 2020

Reassuring news on the Oxford vaccine (AZD1222) against SARS-CoV-2

A new paper from the UK vaccine research group, currently available on the bioRxiv preprint server, reveals that a single dose of ChAdOx1 nCoV-19 (AZD1222) can induce antigen-specific antibody and T cells responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and a booster shot additionally enhances antibody production with an increase in neutralizing titers – particularly in pigs.

22 Jun 2020

UAH researchers assess treatment efficacy of naturally occurring compounds against COVID-19

The Baudry Lab at The University of Alabama in Huntsville has identified 125 naturally occurring compounds that have a computational potential for efficacy against the COVID-19 virus from the first batch of 50,000 rapidly assessed by a supercomputer.

22 Jun 2020

Synthetic peptide could be an effective COVID-19 treatment and SARS-CoV-2 vaccine

Ligandal, one of the world’s leading genetic medicine companies, has modeled a synthetic peptide that could be an effective COVID-19 treatment and SARS-CoV-2 vaccine.

22 Jun 2020

COVID-19 plasma therapy safe and improves survival, says large study

Researchers working on COVID-19 therapy with plasma from convalescent patients have found that it is safe and effective and improves the chances of survival among those who are severely ill. The new study titled, “Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients,” is published as a preprint for the journal Mayo Clinic Proceedings.

20 Jun 2020

MMR vaccine could offer protection against COVID-19

Administering the MMR (measles, mumps, rubella) vaccine could serve as a preventive measure to dampen septic inflammation associated with COVID-19 infection, say a team of experts in this week's mBio, a journal of the American Society for Microbiology.

19 Jun 2020

New therapy provides relief in patients with chronic low back pain

A new study has found that tanezumab, a monoclonal antibody that inhibits nerve activity, provides relief in patients with chronic low back pain, one of the leading reasons why people seek medical care and the number one cause of disability worldwide.

19 Jun 2020

Novel radioisotope therapy could provide favorable prognosis in neuroblastoma patients

Neuroblastoma is one of the most common cancers in children and has limited treatment options.In a new study, researchers from Kanazawa University retrospectively analyzed children with refractory or relapsed high-risk neuroblastoma who were treated with 131I-metaiodobenzylguanidine (131I-MIBG) and discovered a favorable prognosis in these patients.

19 Jun 2020

Human trials to commence using SARS-CoV-2 antibodies from cow's blood

The coronavirus pandemic has sparked a sense of urgency as it actively spreads across the globe. The number of reported cases has now surpassed 8.46 million people, with a death toll of more than 453,000. Scientists and pharmaceutical companies are racing to develop an effective treatment and vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

19 Jun 2020

Convalescent plasma found to be safe for diverse patients with COVID-19

Mayo Clinic researchers and collaborators have found investigational convalescent plasma to be safe following transfusion in a diverse group of 20,000 patients. The findings -- from the U.S. Food and Drug Administration's Expanded Access Program for COVID-19 -- are reported in Mayo Clinic Proceedings.

18 Jun 2020

Crystal structure of SARS-CoV-2 protease-inhibitor in complex with a Chinese herb Shikonin

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has been spreading rampantly over the whole world, infecting millions of people (over 8.45 million at last count), with over 452,000 deaths, as of June 19, 2020. It causes a broad spectrum of disease manifestations, from asymptomatic disease to severe or even fatal respiratory symptoms.

18 Jun 2020

Efficacy News and Research

UK announces research partnership with Atomwise to explore potential COVID-19 therapies

FDA approved drugs active against COVID-19

First clinical trial in South Africa for Covid-19 vaccine begins

Study: Increased use of human antibiotics on rice crops may fuel antibiotic resistance

Jubilant Therapeutics announces preclinical data of dual LSD1 and HDAC6 inhibitor at AACR 2020

Characterizing SARS-CoV-2 convalescent plasma

Growth, adaptation and neutralization of SARS-CoV-2 with acute-phase serum

Three vaccine candidates race to combat SARS-CoV-2

Favipiravir has weak effect on SARS-CoV-2 and Hydroxychloroquine none at all in hamster model

Novel vaccine platform against COVID-19 based on engineered human mesenchymal stem cells

Reassuring news on the Oxford vaccine (AZD1222) against SARS-CoV-2

UAH researchers assess treatment efficacy of naturally occurring compounds against COVID-19

Synthetic peptide could be an effective COVID-19 treatment and SARS-CoV-2 vaccine

COVID-19 plasma therapy safe and improves survival, says large study

MMR vaccine could offer protection against COVID-19

New therapy provides relief in patients with chronic low back pain

Novel radioisotope therapy could provide favorable prognosis in neuroblastoma patients

Human trials to commence using SARS-CoV-2 antibodies from cow's blood

Convalescent plasma found to be safe for diverse patients with COVID-19

Crystal structure of SARS-CoV-2 protease-inhibitor in complex with a Chinese herb Shikonin

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News